Ukr.Biochem.J. 2016; Volume 88, Issue 2, Mar-Apr, pp. 73-81

doi: https://doi.org/10.15407/ubj88.02.073

Physical-chemical properties and the reactivity of pyridoxine and pyrrolidone carboxylate and their protolytic forms

22.04.2016   Uncategorized   No comments

N. Ya. Golovenko, V. B. Larionov, O. V. Karpova

A. V. Bogatsky Physical-Chemical Institute, National Academy
of Sciences of Ukraine, Odessa;
e-mail: lvb_78@ukr.net

Preparation Methadoxine is equimolar salt, which cationic component (pyridoxine) is 3-oxypyridine derivative, possessing B6-vitamine like activity, while anionic component is the cyclic lactame of glutamic acid. Since biopharmaceutical and pharmacological properties of this drug depend on biochemical transformation its components, of the aim of this work was to determine the structure of possible ionized pyridoxine and pyrrolidone carboxylate forms and their reaction ability in biochemical processes. Physical-chemical properties of compounds (pKa, logP, logD, proton donor/acceptor quantity, solubility (g/l)) were calculated with ACD/pKaDB program or obtained from Pub-Med physical/chemical properties database. UV spectra of compounds were obtained after dissolution in different pH solutions (1.0, 4.5 and 6.8). It was found that at different pH values one can observe changes of the absorption spectra due to the presence of prevailing amount of the protonated form.  An analysis of both pKa, logP and logD indicators and reactive functional groups of Methadoxine components has revealed that they can be protonated in different regions of gastro-intestinal tract, that influences their solubility in hydrophilic and lypophilic media. Pharmacological properties of pyridoxine and pyrrolidone carboxylate themselves are performed after their preliminary biotransformation to active metabolites. Only ionic interaction between Methadoxine components in the substance composition can appear, that provides its pharmaceutical stability and ensures its activity only in the orga­nism conditions.

Keywords: , , , ,

References:

  1. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol. 2000;32(1 Suppl):39-47. PubMed, CrossRef
  2. Pera N, Phung N, Farrell GC. Oxidative stress in hepatic fibrogenesis: implications from a nutritional model of nonalcoholic steatohepatitis. Hepatology. 1999; 30:493A.
  3. Sukhareva GV.  Alcoholic liver disease. Consilium medicum. Gastroenterology. 2003; 5(3): 26-27.
  4. Addolorato G, Ancona C, Capristo E, Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol. 2003 Sep-Dec;16(3):207-14. PubMed
  5. Díaz Martínez MC, Díaz Martínez A, Villamil Salcedo V, Cruz Fuentes C. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res. 2002 Jan-Feb;30(1):44-51. PubMed, CrossRef
  6. Golovenko MYa, Borysyuk IYu, Karpova OV, Vorozhbyt AP. An experimental evaluation of the preventive effect of alcodez on ethanol-induced impairment of learning in white rats. Odessa Med J. 2012;6:42-45.
  7. Golovenko NY, Borisyuk IYu, Karpova OV, Vorozhbyt A.P. An experimental evaluation of the preventive effect of metadoxine on ethanol’s acute neurotoxic effect. Visnyk Psykhiatriyi ta Psykhofarmakoterapiyi. 2012;1(21):36-41.
  8. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-9. PubMed, CrossRef
  9. Ink SL, Henderson LM. Vitamin B6 Metabolism. Annu Rev Nutr. 1984;4(1): 455-70. CrossRef
  10. Biochemical Nomenclature and Related Documents, 2nd edition, Portland Press, 1992, p.269-271.
  11. Dobson CM. The nature and significance of protein folding. In Mechanisms of Protein Folding 2nd ed. Ed. RH Pain. Frontiers in Molecular Biology series. Oxford University Press: NY, 2000. 365р.
  12. Van der Werf P, Orlowski M, Meister A. Enzymatic conversion of 5-oxo-L-proline (L-pyrrolidone carboxylate) to L-glutamate coupled with cleavage of adenosine triphosphate to adenosine diphosphate, a reaction in the -glutamyl cycle. Proc Natl Acad Sci USA. 1971 Dec;68(12):2982-5. PubMed, PubMedCentral, CrossRef
  13. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int. 2007 Jun;50(7-8):941-53. PubMed, CrossRef
  14. Calabrese V, Calderone A, Ragusa N, Rizza V. Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res. 1996;22(1):17-24. PubMed
  15. Calabrese V, Calderone A, Ragusa N, Rizza V. Effects of metadoxine on cellular formation of fatty acid ethyl esters in ethanol treated rats. Int J Tissue React. 1995;17(3):101-8. PubMed
  16. Fehér J., Váli L., Blázovics A., Lengyel G.  The beneficial effect of metadoxine (pyridoxine-pyrrolidone-carboxylate) in the treatment of fatty liver diseases. Clin Exp Mel J. 2009;3(1): 65-79. CrossRef
  17. Felicioli R, Saracchi I, Flagiello AM, Bartoli C. Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. Int J Clin Pharmacol Ther Toxicol. 1980 Jun;18(6):277-80. PubMed
  18. Calabrese V, Carlino S, Chinnici V, De Bernardis E, Rizza V. La metadoxina modula le cinetiche di assorbimento, metabolismo ed eliminazione dell’etanolo. Revista Italiana di Alcologia. 1986;5:44-49.
  19. Lv Y, Kang ZS, Liu Y, Li TY, Xiao YH. Pharmacokinetics of metadoxine injection in healthy volunteers. Chin J Clin Pharmacol. 2006; (1):55-58.
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.